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Hepatocellular carcinoma (HCC) has limited systemic treatment options and a poor 
prognosis. The immune checkpoint inhibitor pembrolizumab was recently approved 
for treatment of solid tumors with microsatellite instability (MSI). However, its 
clinical utility for the management of HCC remains to be clarified. Here, we present a 5 
case of unresectable HCC with MSI that showed an impressive response to 
pembrolizumab treatment. 
A 64-year-old man with chronic HCV infection was diagnosed with a large HCC. 
His severe liver dysfunction and poor performance status prevented any treatment 
option other than sorafenib. However, sorafenib failed after a few days due to rapid 10 
progression of the tumor. Based on the finding of MSI in a biopsy specimen, 
immunotherapy using pembrolizumab was initiated. A dramatic improvement in his 
general condition and a reduction in tumor size were observed after the initiation of 
pembrolizumab treatment. Among a cohort of 50 consecutive patients with advanced 
HCC who were refractory to standard systemic therapy, MSI was found only in the 15 
present case. 
Immune checkpoint blockade therapy induced prominent anti-tumor effects in HCC 
with MSI. Screening for defects in DNA mismatch repair function may be warranted 
in HCC patients despite the low frequency of MSI. 
 20 
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Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related 
death worldwide, and the prognosis of unresectable HCC is considerably poor [1, 2]. 
Although the multikinase inhibitor sorafenib has been widely used as first-line 
chemotherapy, its objective response rate is low (2%), with a complete response rate 5 
of 0% observed in two randomized controlled trials of patients with advanced HCC 
[3, 4]. Lenvatinib was recently approved as a systemic treatment for HCC, and it 
showed a higher response rate (40%) in patients with unresectable HCC [5]. However, 
its toxicity often leads to early termination of the treatment and a reduced benefit 
among patients with impaired hepatic reserve function. 10 
Pembrolizumab is a humanized IgG4 monoclonal antibody that inhibits the 
programmed cell death 1 (PD-1) protein, activating a host immune response against 
tumor cells [6]. In pivotal phase 2 studies, a prominent antitumor effect of 
pembrolizumab was recognized in patients with solid tumors exhibiting microsatellite 
instability (MSI) [7]. Consequently, pembrolizumab was quickly approved in many 15 
countries for the treatment of unresectable or metastatic solid MSI tumors that 
progressed after prior systemic treatment and are poor candidates for other treatment 
options. Since the clinical trials contributing to the approval of pembrolizumab did not 
include a wide variety of tumors, its practical use as a systemic treatment for HCC 
remains unknown. Furthermore, the incidence of MSI in unresectable tumors has not 20 
been thoroughly clarified. 
Here, we describe an impressive case of MSI HCC that exhibited a dramatic 
response to pembrolizumab.   






The patient was a 64-year-old male with a medical history of diabetes. His family 
history included lung cancer in his mother and diabetes in his father. Although he was 
diagnosed with chronic HCV infection at the age of 40 years, he refused to receive 
any antiviral treatment. In December 2018, he presented to his family physician with 5 
weight loss and intermittent abdominal pain that had persisted for 3 months. After the 
detection of a large hepatic mass by computed tomography (CT), he was referred to 
our hospital for further diagnosis and management. 
On physical examination, he had a debilitating fever and serious abdominal 
discomfort that resulted in a poor performance status. Blood test results showed severe 10 
liver dysfunction indicating Child–Pugh class B and extremely elevated levels of des-
γ-carboxy prothrombin (DCP) (Table 1). Contrast-enhanced CT revealed an invasive 
liver tumor 13 × 10 cm in size. 18-fluorodeoxyglucose positron emission tomography 
showed strong uptake in the main tumor and widespread invasion to the lymph nodes 
(Fig. 1). Percutaneous liver biopsy prior to treatment revealed moderately 15 
differentiated hepatocellular carcinoma (Fig. 2a).  
Although the patient had Child-Pugh B liver function, he had advanced HCC with 
extra hepatic metastasis and vascular invasion. Therefore, we decided to administer 
sorafenib to this patient. In initiation of sorafenib to patients, strict informed consent 
was performed. However, after systemic treatment with sorafenib was started, his 20 
general condition continued to deteriorate. CT indicated progressive disease and a 
remarkably enlarged tumor. An additional biopsy showed an MSI-H tumor. Relatively 
high programmed death-ligand 1 (PD-L1) expression and the presence of CD8+ 





lymphocytes in the main tumor were observed (Fig. 2b, 2c). Based on these findings, 
pembrolizumab treatment was initiated. The patient’s physical condition and liver 
function improved immediately, and the tumor marker levels had recovered to within 
their normal ranges by the end of two treatment cycles. Imaging studies showed 
exceptional shrinkage of the tumor accompanied by decreased tumor vascularity and 5 
viability (Fig. 3). Furthermore, histopathological assessment of a tumor biopsy 
specimen obtained after four cycles of treatment showed extensive necrosis with no 
evidence of viable cancer cells (Fig. 4). The therapeutic effect was determined to be a 
complete response, as assessed by the modified Response Evaluation Criteria in Solid 
Tumors. The patient has been receiving pembrolizumab treatment for over 4 months, 10 
without any side effects or sign of recurrence. 
Between January and June 2019, we investigated the prevalence of MSI in 50 
consecutive HCC patients with unresectable disease that had progressed after standard 
chemotherapy. Using a companion diagnostic sequencing kit (polymerase chain 
reaction analysis of five microsatellite markers: BAT25, BAT26, NR21, NR24, and 15 
MONO27), we successfully performed the tests in biopsy specimens, even very small 
ones, obtained from liver tumors. As a result, MSI was found only in the present case 
(2%), in which all five markers showed slight shortening (Fig. 5). 
  






 We describe a case of MSI-H HCC that showed a favorable response to 
pembrolizumab therapy. To our knowledge, no other report has addressed the MSI 
status or efficacy of immune checkpoint blockade therapy in advanced HCC. 
 We established the importance of determining the MSI status of tumors in a 5 
population with a substantially low incidence of MSI. T cells attack the tumor by 
recognizing tumor specific antigens. At the same time, T cells trigger the expression 
of PD-L1 molecules, and PD-L1 molecules bind to PD-1. Then, signals that 
negatively affect tumor immunity are delivered to cytotoxic T cells, reducing T cell 
activity and resulting in immune escape or tolerance [8]. The administration of PD-1 10 
antibodies such as pembrolizumab demonstrate anti-tumor effect by unlocking this 
immune mechanism and restoring the ability of the immune system to attack tumor 
cells [9]. On the other hand, Le DT et al identified more potential new mutation-
associated antigens in tumors of mismatch repair-deficient cancers compared to 
mismatch repair-proficient cancers [10]. As a result, in patients with MSI, it is 15 
considered that T cells are more likely to recognize tumor cells and anti-PD1 
treatment is very effective. However, the prevalence of MSI was very rare, as 
expected. In general, mismatch repair deficiency is more common in early-stage 
cancers, and to date, the presence of MSI in late-stage HCC has not been reported 
[11]. Despite the low prevalence of MSI, the low cost and good benefit seen in 20 
patients suggest the necessity of MSI testing in poor HCC candidates for standard 
treatments. 





Given the extraordinary response observed in our patient, mismatch repair function 
should be considered a biomarker guiding systemic treatment decisions for HCC. 
According to a previous report evaluating the efficacy and safety of pembrolizumab 
for HCC in a second-line setting [12], the objective response and complete response 
rates were only 18.3% and 2.2%, respectively. Determining the MSI status may help 5 
identify the patients who would benefit the most from this novel immunotherapy. 
Additionally, we assume two important factors enhanced the anti-tumor effect in the 
present case. First, prolonged inflammation in the liver caused by untreated hepatitis 
may facilitate the evolutionary process of MSI-related hepatocarcinogenesis. 
Hepatitis-associated DNA methylation influences a considerable number of 10 
oncogenes and tumor-suppressor genes [13]. Once methylation and gene silencing of 
mismatch repair genes occur, the tumor mutation burden may increase exponentially 
under persistent inflammatory conditions such as chronic hepatitis and may contribute 
to remarkable immunogenicity. Second, the present case initially had a distinct “hot” 
immune phenotype in terms of PD-L1 expression and immune cell infiltration. Less 15 
than 20% of all HCC patients are PD-L1 positive [14], and most HCC patients have a 
low amount of CD8+ T-cell infiltration [15]. On the other hand, the relationship 
between the immunological condition and MSI status of a tumor has not been fully 
investigated in HCC. Accumulation of enough patients to obtain adequate power for 
genomic analyses and profiling of the tumor immune microenvironment is warranted 20 
for better understanding of the biology of MSI HCC. 
Here, we report a patient with MSI-H advanced HCC that showed a complete 
response to pembrolizumab. We propose that the MSI status should be determined in 









HCC: hepatocellular carcinoma; MSI: microsatellite instability; PD-1: programmed 5 
cell death 1; CT: computed tomography; DCP: des-γ-carboxy prothrombin; PD-L1: 
programmed death-ligand 1.  
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Table 1. Blood test results. 
CBC  γGTP 505 IU/L Viral markers 
Leukocyte count 9760/μL Na 134 mEq/L HBs antigen (-) 
Erythrocyte count 3.78×106/μL K 3.7 mEq/L HCV antibody (+) 
Hemoglobin 10.8 g/dL Cl 102 mEq/L HCV-RNA 4.8 logIU/mL 
Hematocrit 32.5% TP 8.4 g/dL genotype 1b 
Platelet count 314×103/μL Albumin 2.5 g/dL Liver function 
Blood coagulation test BUN 20.8 mg/dL ICG-R 14.2% 








Blood chemistry NH3 33 μmol/L   
Total bilirubin 1.2 mg/dL HbA1c 5.3%   
AST 74 IU/L Tumor markers   
ALT 80 IU/L AFP 1.3 ng/mL   
LDH 274 IU/L AFP-L3 <0.5%   
ALP 1516 IU/L DCP 16052 mAU/mL   
 





BUN, blood urea nitrogen; TP, total protein; PT-INR, prothrombin time-international 
normalized ratio; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; ALP, 
alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; Cr, creatinine; CRP, C-reactive protein; LDH, lactate 
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Figure 1. Contrast-enhanced CT findings. (a) The tumor (13 cm in diameter) showed 
early-phase enhancement in the portal region of the liver. (b) The equilibrium phase of 
CT showed that the tumor was slightly hypodense. (c, d) The tumor had invaded the 
left portal vein and inferior vena cava. (e) Positron emission tomography/CT showed a 5 
maximum standardized uptake value of 6.8 in the main tumor and of 3.4 in the para-
aortic lymph node metastasis. 
Figure 2. Histopathological findings in the liver tumor. (a) The tumor was moderately 
differentiated hepatocellular carcinoma (hematoxylin and eosin staining, ×200). (b) 
Immunohistochemical examination revealed positive PD-L1 expression in a portion 10 
(5%) of the tumor cells (×200). (c) Diffuse tumor infiltration by CD8⁺ lymphocytes 
was evident (×200).  
Figure 3. Clinical course. Over the course of the treatment, changes were evident in 
DCP level and in the arterial phase of contrast-enhanced CT images. Despite having 
started sorafenib therapy, the tumor size and tumor marker levels increased. However, 15 
both showed dramatic improvements upon initiation of pembrolizumab treatment. 
DCP, des-γ-carboxy prothrombin; PS, performance status. 
Figure 4. Histopathological findings after pembrolizumab therapy. (a) Hematoxylin 
and eosin staining showed extensive necrosis and no cancer cells (×100). (b) CD8+ 
lymphocyte infiltration persisted around the necrotic tumor tissue (×200). (c) 20 
Immunostaining of Foxp3 showed almost no regulatory T cells in the tumor (×200). 





Figure 5. Polymerase chain reaction analysis of five microsatellite markers. In all 
markers, the waveform peak of tumor tissue was shifted to the left compared to that of 
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